07:00 , Jul 19, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting AGRP on obesity

Researchers in New York have identified G protein-coupled receptor 17 as a target on agouti related protein -expressing neurons, which are known to regulate multiple factors related to obesity. 1 The findings open up a...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Agouti related protein (AGRP); forkhead box O1 (FOXO1); G protein-coupled receptor 17 (GPR17) Mouse and in vitro studies suggest inhibiting FOXO1-GPR17 signaling could...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Serotonin (5-HT3) receptor Studies in mice suggest 5-HT3 receptor antagonists could help treat anorexia. In mice, pharmacological destruction of the agouti-related protein (AGRP)-expressing neurons...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after...
07:00 , Aug 28, 2008 |  BC Innovations  |  Targets & Mechanisms

Curbing Mitochondrial Appetite

Several companies have tried and failed to develop obesity drugs that agonize mitochondrial uncoupling proteins, which let adipose cells generate heat by burning excess fat. A new study now suggests that one member of this...
08:00 , Nov 5, 2007 |  BioCentury  |  Product Development

Targeting obesity subgroups

Both of the obesity therapeutics Orexigen Therapeutics Inc. is developing are oral, twice-daily combinations of approved drugs that include extended-release bupropion as one of their components. But the second component of each gives the two...
08:00 , Mar 15, 1999 |  BioCentury  |  Tools & Techniques

Targeting mahogany

The most straightforward mechanism for a small molecule therapeutic agent is to inactivate the product of a single gene. However for diseases with a complex genetic basis it may be difficult to identify a single...
08:00 , Dec 14, 1998 |  BC Week In Review  |  Company News

Amgen other research news

AMGN researchers published in Biochemistry the finding that purified full-length AGRP or a truncated version of the protein acts as an antagonist of melanocortin receptors 3 and 4 (MC-3 and MC-4). AGRP is known to...
07:00 , Oct 6, 1997 |  BC Week In Review  |  Company News

Stanford University School of Medicine other research news

University researchers published in Science the identity of a protein that is nearly identical in structure to the Agouti protein implicated in a mouse model of obesity. The newly recognized protein was isolated from mice...